Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2Skin Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × oblimersen × Clear all
NCT00016263 2014-01-06

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
Dermatologic

Melanoma

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡